This article explains how AI tools can validate regulatory dossiers, catch technical errors before submission, and minimize rework for emerging biotech companies.

Examines the evolution of eCTD systems from specialized publishers for regulatory submissions to enterprise platforms that serve as a unified drug lifecycle archive.